Lupus Nephritis Market Growth Accelerates in 2024-2034 Forecast Period

The Lupus Nephritis market is set for rapid growth driven by increasing prevalence, awareness, and pipeline launches, transforming dynamics from 2024-2034.

DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034" report delivers detailed analysis of epidemiology trends, market outlook, drug uptake, and treatment scenarios in the US, EU5 (Germany, Spain, Italy, France, UK), and Japan.

To Know in detail about the Lupus Nephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lupus Nephritis Market Forecast https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key facts:

• Market size to grow at significant CAGR (2020-2034).
• FDA approved Allogene's IND for ALLO-329 in Feb 2025; Phase 1 trial for SLE/LN starts mid-2025.
• Adicet Bio dosed first LN patient in Phase I for ADI-001 in Nov 2024.
• Kyverna to share KYV-101 LN data in Nov 2024.
• US market ~USD 1,500M in 2023.
• Emerging therapies like GAZYVA/GAZYVARO (obinutuzumab) and SAPHNELO (anifrolumab) to reshape treatment.
• SAPHNELO to generate >USD 300M in US by 2034.
• US holds >80% of 7MM share (2023), followed by Japan and Spain.
• EU4+UK ~USD 300M in 2023.
• LN more prevalent in children (32-55%), often severe.
• ~660,000 SLE cases in 7MM (2023).
• Key companies: Hoffmann-La Roche, Genentech, AstraZeneca, Equillium, Novartis, BeiGene, Boehringer Ingelheim, Otsuka, Chugai, Astellas, Mitsubishi Tanabe, I-Mab, Hanmi, LG Chem, TWi Biotechnology, APRINOIA Therapeutics, OBI Pharma.
• Key therapies: Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Itolizumab, Myfortic, Zanubrutinib, Voclosporin (Lupkynis), TJM2, HMPL-523, Tigulixostat, AC-201, OBI-888.

Lupus Nephritis Overview: A severe SLE complication causing kidney inflammation via autoimmune attacks.

Get a Free sample for the Lupus Nephritis Market Report: https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Epidemiology: Covers 7MM trends (2020-2034), including total prevalence, cases by severity/gender, and diagnosed episodic/chronic cases.

Download to explore drivers @ Lupus Nephritis Epidemiological Insights https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Market dynamics will shift with therapies like Obinutuzumab and Myfortic (2020-2034). Key therapies/companies: LUPKYNIS (voclosporin, Aurinia/Otsuka; MHLW approved Sep 2024, launched Nov 2024 in Japan as first oral targeted LN therapy); BENLYSTA (belimumab, GSK); SAPHNELO (anifrolumab, AstraZeneca; Phase 3 LN trial includes Japan); GAZYVA/GAZYVARO (obinutuzumab, Roche/Chugai; Phase 3 in Japan for SLE/LN); others include Mycophenolate Mofetil (Genentech), Itolizumab (Equillium), Myfortic (Novartis), Zanubrutinib (BeiGene), Tacrolimus (Mitsubishi Tanabe; Phase 2/3 in Asia), TJM2 (I-Mab; Phase 2 LN), HMPL-523 (Hanmi; Phase 2 lupus), Tigulixostat (LG Chem; Phase 1/2), AC-201 (TWi Biotechnology; Phase 2 LN), OBI-888 (OBI Pharma; Phase 1).

To know more about treatments, visit @ Lupus Nephritis Medications https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Drivers: Rising research, prevalence, clinical studies. Barriers: High costs, need for novel/targeted therapies.

Scope: 2020-2034, 7MM. Includes assessments, dynamics, competitive analysis, unmet needs, KOL views.

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

Lupus Nephritis - Epidemiology Forecast - 2034

DelveInsight’s ‘Lupus nephritis – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. The leading Lupus Nephritis Companies developing therapies include - AstraZeneca, Novartis, Roche, Alexion Pharmaceuticals, Cabaletta Bio, AbelZeta, and others.

Lupus Nephritis - Pipeline Insight, 2026

DelveInsight’s, “Lupus Nephritis - Pipeline Insight, 2026” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. The leading Lupus Nephritis Companies developing therapies include - AstraZeneca, Novartis, Roche, Alexion Pharmaceuticals, Cabaletta Bio, AbelZeta, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com